ClinicalTrials.gg
RecruitingNCT07011732Updated Nov 6, 2026

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

A Phase 3 interventional study of Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule in Alzheimer Disease, sponsored by Bristol-Myers Squibb. Recruiting at 162 sites in 15 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 6, 20265 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
6th of 10
426 · median 463
Started
2025
with 4 others
Phase 3
10 of 10
10 open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
Bristol-Myers Squibb

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 6th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 9th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology: i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.

ii) If no historical evidence available: A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.

B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:

  • Amyloid PET.
  • Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.

    • (MMSE) score of ≤ 24 at Screening (Visit 1).
    • Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:

      i) Attend all visits and report on participant's status. ii) Oversee participant compliance with medication and study procedures. iii) Participate in the study assessments and provide to participate in the study.

    • History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).
    • AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).
    • CMAI-IPA Total Score ≥ 30 at Screening (Visit 1) and Baseline (Visit 2).

Exclusion criteria

Exclusion Criteria

- Medical Conditions: i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.

ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder. iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.

iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.

- Prior/Concomitant Therapy: i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).

A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.

B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).

C. Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).

- Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
426 participants (estimated)

Study arms

  • Experimental
    KarXT + KarX-EC

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline/Trospium Chloride Capsule

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: KarXT, BMS-986510

  • Specified dose on specified days

    Also known as: KarX-EC, BMS-986519

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score at Week 14

    Time frame: At Week 14

Secondary outcomes

  1. Change from baseline on the Clinical Global Impressions-Severity (CGI-S) at Week 14

    Time frame: At Week 14

  2. Change from baseline on the CMAI-IPA Domains at Week 14

    Time frame: At Week 14

  3. Change from baseline on the CMAI Total Score at Week 14

    Time frame: At Week 14

  4. Number of participants with Occurrence of Response at Week 14

    As determined by CMAI-IPA Total Score changes of at least 30%, 40%, and 50% from baseline

    Time frame: At Week 14

  5. Change from baseline on the Neuropsychiatric Inventory/Neuropsychiatric Inventory -Nursing Home (NPI/NPI-NH) Total Score at Week 14

    Time frame: At Week 14

  6. Number of participants with Adverse Events (AEs)

    Time frame: Up to Week 18

  7. Number of participants with Treatment Emergent AEs (TEAEs)

    Time frame: Up to Week 18

  8. Number of participants with Serious AEs (SAEs)

    Time frame: Up to Week 18

  9. Number of participants with AEs leading to study drug withdrawal

    Time frame: Up to Week 14

  10. Number of deaths

    Time frame: Up to Week 18

  11. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to Week 18

  12. Barnes Akathisia Rating Scale (BARS)

    Time frame: Up to Week 14

  13. Abnormal Involuntary Movement Scale (AIMS)

    Time frame: Up to Week 14

  14. Body Weight

    Time frame: Up to Week 14

  15. Body Mass Index (BMI)

    Time frame: Up to Week 14

  16. Number of participants with vital sign abnormalities

    Time frame: Up to Week 18

  17. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Week 14

  18. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to Week 14

  19. Number of participants with suicidal ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Week 18

  20. Severity of benign prostatic hyperplasia in male participants as assessed by International Prostate Symptom Score (IPSS)

    Time frame: Up to Week 14

07

Study locations

120 of 162 sites recruiting
  • Imaging Endpoints
    Scottsdale, Arizona 85258, United States
    Recruiting
    • Nida Laurin, Site 1619 · Contact480-290-1547
  • Advanced Research Center (ARC) - Anaheim
    Anaheim, California 92805, United States
    Recruiting
    • Steven Macina, Site 1657 · Contact714-999-6688
  • Local Institution - 1668
    Fresno, California 93710, United States
    Not yet recruiting
    • Site 1668 · Contact
  • Local Institution - 1637
    La Jolla, California 92037, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Neurology Group
    Pomona, California 91767, United States
    Recruiting
    • Sadiq Altamimi, Site 1662 · Contact
  • Local Institution - 1639
    Torrance, California 90505, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
    Recruiting
    • Ira Glick, Site 1651 · Contact925-298-5147
  • Local Institution - 1630
    Colorado Springs, Colorado 80907, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1622
    Maitland, Florida 32751, United States
    Not yet recruiting
    • Site 1622 · Contact
  • Local Institution - 1631
    Maitland, Florida 32751, United States
    Not yet recruiting
    • Site 1631 · Contact
  • Flourish Research
    Merritt Island, Florida 32952, United States
    Recruiting
    • David Kirk, Site 1666 · Contact321-305-5015
  • Local Institution - 1602
    Miami, Florida 33122, United States
    Not yet recruiting
    • Site 1602 · Contact
  • Local Institution - 1618
    Miami, Florida 33135, United States
    Not yet recruiting
    • Site 1618 · Contact
  • Local Institution - 1604
    Miami, Florida 33186, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1608
    Ocala, Florida 34471, United States
    Not yet recruiting
    • Site 1608 · Contact
  • Combined Research Orlando (CRO)
    Orlando, Florida 32807, United States
    Recruiting
    • Eric Carbonell, Site 1635 · Contact407-440-4493
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
    Recruiting
    • Alexander White, Site 1612 · Contact386-304-7070
  • Hope Research Network - Miami
    Virginia Gardens, Florida 33166, United States
    Recruiting
    • Jorge Jorge, Site 1609 · Contact786-681-4959
  • Local Institution - 1655
    Marrero, Louisiana 70072, United States
    Not yet recruiting
    • Site 1655 · Contact
  • CBH Health
    Gaithersburg, Maryland 20877, United States
    Recruiting
    • Elia Acevedo Diaz, Site 1636 · Contact301-251-4702
  • Local Institution - 1663
    Foxborough, Massachusetts 02035-1309, United States
    Not yet recruiting
    • Site 1663 · Contact
  • Boston Center for Memory
    Newton, Massachusetts 02459, United States
    Recruiting
    • Paul Solomon, Site 1638 · Contact413-281-0577
  • Mayflower Clinical Research
    South Dartmouth, Massachusetts 02747, United States
    Recruiting
    • Mushtaque Chachar, Site 1642 · Contact508-925-7403
  • Voltaire Springfield
    Springfield, Massachusetts 01103, United States
    Recruiting
    • Brittany Perreault, Site 1660 · Contact413-305-1142
  • NeuroBehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
    Recruiting
    • Richard Jackson, Site 1665 · Contact412-916-2425
  • Oakland Medical Research
    Troy, Michigan 48085, United States
    Recruiting
    • Jay Sandberg, Site 1620 · Contact248-687-7412
  • Local Institution - 1667
    St Louis, Missouri 63128, United States
    Not yet recruiting
    • Site 1667 · Contact
  • Redbird Research
    Las Vegas, Nevada 89119, United States
    Recruiting
    • Jelena Kunovac, Site 1649 · Contact760-758-2222
  • Local Institution - 1647
    Middletown, New Jersey 07748, United States
    Completed

    Not enrolling at this site — choose another above.

  • Global Medical Institutes LLC; Princeton Medical Institute
    Princeton, New Jersey 08540, United States
    Recruiting
    • Matthew Adasofunjo, Site 1664 · Contact
  • Local Institution - 1610
    Inwood, New York 11096, United States
    Not yet recruiting
    • Site 1610 · Contact
  • Local Institution - 1656
    New Windsor, New York 12553, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Five Towns Neurology PC -Woodmere - 923 Broadway
    Woodmere, New York 11598-1739, United States
    Recruiting
    • David Steiner, Site 1658 · Contact516-239-1800
  • Local Institution - 1645
    Woodmere, New York 11598-1739, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Central States Research
    Tulsa, Oklahoma 74136, United States
    Recruiting
    • Sarah Land, Site 1640 · Contact918-645-5400
  • Local Institution - 1652
    Columbia, South Carolina 29205, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Advanced Neurology Epilepsy and Sleep Center
    El Paso, Texas 79902, United States
    Recruiting
    • Aamr Herekar, Site 1643 · Contact505-903-1715
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
    Recruiting
    • Nicholas Hanson, Site 1641 · Contact
  • The Memory Clinic
    Bennington, Vermont 05201-9810, United States
    Recruiting
    • Lisa Catapano-Friedman, Site 1646 · Contact413-281-0575
  • Local Institution - 1644
    Seattle, Washington 98122, United States
    Not yet recruiting
    • Site 1644 · Contact
  • Local Institution - 1654
    Spokane, Washington 99201, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1001
    La Plata, Buenos Aires 1900, Argentina
    Not yet recruiting
    • Site 1001 · Contact
  • Local Institution - 1002
    Mar del Plata, Buenos Aires B7602CBM, Argentina
    Not yet recruiting
    • Site 1002 · Contact
  • CEN Centro Especializado en Neurociencias
    Córdoba, Córdoba Province 5004, Argentina
    Recruiting
    • Hernan Ruggeri, Site 1004 · Contact93515339477
  • Fundacion Estudios Clinicos
    Rosario, Santa Fe Province S2000DEJ, Argentina
    Recruiting
    • Javier Travella, Site 1006 · Contact
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI)
    Buenos Aires, C1428AQK, Argentina
    Recruiting
    • Ricardo Allegri, Site 1003 · Contact5491144704855
  • Instituto Privado Kremer
    Córdoba, 5004, Argentina
    Recruiting
    • Leonardo Kremer, Site 1005 · Contact543515000000
  • Centro Medico Luquez
    Córdoba, 5006, Argentina
    Recruiting
    • Juan Luquez, Site 1000 · Contact+5493517481586
  • L2IP - Instituto de Pesquisas Clínicas
    Brasília, Federal District 70200730, Brazil
    Recruiting
    • Eduardo Vasconcellos, Site 1051 · Contact55-6199983-1080
  • CECPAR - Centro de Estudos Clínicos do Paraná
    Curitiba, Paraná 80030-310, Brazil
    Recruiting
    • Luiz Petry, Site 1053 · Contact+5541988668732
  • PUCTrials
    Curitiba, Paraná 80230-130, Brazil
    Recruiting
    • Carlos Twardowschy, Site 1052 · Contact5541999260355
  • Nucleo de Pesquisa Clinica do Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
    Recruiting
    • Clarissa Gama, Site 1058 · Contact+55 51 999885851
  • Hospital Moinhos de Vento
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
    Recruiting
    • Wyllians Borelli, Site 1054 · Contact5551991019123
  • Instituto de Pesquisa Clínica de Campinas
    Campinas, São Paulo 13060-080, Brazil
    Recruiting
    • Alexandre Pieri, Site 1057 · Contact(5519)32670023
  • Ruschel Medicina e Pesquisa Clínica
    Rio de Janeiro, 22270-060, Brazil
    Recruiting
    • Sandra Ruschel, Site 1050 · Contact5521999822072
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
    Recruiting
    • Leonel Takada, Site 1055 · Contact5511971539018
  • Clinica Viver - Centro de Desospitalizacao Humana
    São Paulo, 04020-060, Brazil
    Recruiting
    • Claudiane Daltion, Site 1056 · Contact551159087222
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
    Recruiting
    • Mariya Alexandrova-Stoycheva, Site 1101 · Contact360+11
  • Outpatient Clinic for Individual Practice for Specialized Medical Care in Psychiatry - Dr. Madlena Dimitrova Borisova
    Razgrad, 7200, Bulgaria
    Recruiting
    • Madlena Borisova, Site 1103 · Contact+359 88 991 2216
  • Medical Center Sveti Naum EOOD
    Sofia, 1113, Bulgaria
    Recruiting
    • Assen Karadaliev, Site 1100 · Contact35929702117
  • Local Institution - 1104
    Sofia, 1202, Bulgaria
    Not yet recruiting
    • Site 1104 · Contact
  • Medical Center Mladost
    Varna, 9020, Bulgaria
    Recruiting
    • Hristo Kozhuharov, Site 1102 · Contact35952555695
  • Local Institution - 1153
    Hamilton, Ontario L8M 1W9, Canada
    Not yet recruiting
    • Site 1153 · Contact
  • Local Institution - 1755
    London, Ontario N6A 5W9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • London Health Sciences Centre-Victoria Campus
    London, Ontario N6A 5W9, Canada
    Recruiting
    • Tuoyo Awani, Site 1155 · Contact519-685-8500 x77024
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Sandra Black, Site 1151 · Contact416-480-6100 x4551
  • Centre for Addiction & Mental Health
    Toronto, Ontario M6J 1H4, Canada
    Recruiting
    • Sanjeev Kumar, Site 1154 · Contact416-535-8501 x32589
  • Ontario Shores Centre For Mental Health Sciences
    Whitby, Ontario L1N 5S9, Canada
    Recruiting
    • Amer Burhan, Site 1152 · Contact905-430-4055 x6268
  • Local Institution - 1150
    Montreal, Quebec H4A 3T2, Canada
    Not yet recruiting
    • Site 1150 · Contact
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing Municipality 100053, China
    Recruiting
    • Yi Tang, Site 1805 · Contact+8613811021432
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality 100088, China
    Recruiting
    • Qinge Zhang, Site 1810 · Contact
  • Peking University Sixth Hospital
    Haidian District, Beijing Municipality 100191, China
    Recruiting
    • Huali Wang, Site 1815 · Contact+86-10-82806167
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 630014, China
    Recruiting
    • Yang Lv, Site 1813 · Contact+861361823653
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 0, China
    Recruiting
    • Yuping Ning, Site 1809 · Contact+861392221423
  • Shenzhen Kangning Hospital
    Shenzhen, Guangdong 518118, China
    Recruiting
    • Yongjun Wang, Site 1818 · Contact8613632587615
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangzhou Province 510260, China
    Recruiting
    • Jun Liu, Site 1802 · Contact+862081332621
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
    Recruiting
    • Lu Shen, Site 1803 · Contact073189753041
  • Nanjing Drum Tower hospital
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Yun Xu, Site 1801 · Contact+86 13914764479
  • Local Institution - 1800
    Shanghai, Shanghai Municipality 200025, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1811
    Shanghai, Shanghai Municipality 200065, China
    Not yet recruiting
    • Site 1811 · Contact
  • Mental Health Center of Xi'an City
    Xian, Shanxi 710061, China
    Recruiting
    • Wei Dang, Site 1816 · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Weihong Kuang, Site 1819 · Contact+861898060171
  • Tianjin Anding Hospital
    Tianjin, Tianjin Municipality 300074, China
    Recruiting
    • Jie Li, Site 1814 · Contact+862288188006
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Ning Wei, Site 1804 · Contact+86 13957162835
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    Hangzhou, 310016, China
    Recruiting
    • Wei Chen, Site 1817 · Contact+86 138 0573 6335
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, 650032, China
    Recruiting
    • Jin Lu, Site 1812 · Contact8613944802410
  • Local Institution - 1808
    Tianjin, 300350, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1550
    Zagreb, City of Zagreb 10000, Croatia
    Not yet recruiting
    • Site 1550 · Contact
  • Poliklinika Bonifarm-Hondlova 2/11
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Tanja Potocki Karacic, Site 1553 · Contact+38512446968
  • Klinicki Bolnicki Centar Rijeka
    Rijeka, 51000, Croatia
    Recruiting
    • Vladimir Sabljic, Site 1554 · Contact+385 98 369 555
  • Clinical Hospital Center Split
    Split, HR-21000, Croatia
    Recruiting
    • Trpimir Glavina, Site 1551 · Contact38598422557
  • General Hospital Varazdin
    Varaždin, 42000, Croatia
    Recruiting
    • Spomenka Kidemet-Piskac, Site 1552 · Contact
  • Local Institution - 1555
    Zagreb, 10 090, Croatia
    Not yet recruiting
    • Site 1555 · Contact
  • University Hospital of Patras
    Pátrai, Achaḯa 26504, Greece
    Recruiting
    • John Ellul, Site 1200 · Contact+306932447636
  • Henry Dunant Hospital Center
    Athens, Attica 115 26, Greece
    Recruiting
    • Konstantina Yiannopoulou, Site 1205 · Contact+302107796309
  • Aiginiteio University Hospital
    Athens, Attikí 115 28, Greece
    Recruiting
    • Nikolaos Scarmeas, Site 1206 · Contact
  • University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"
    Chaïdári, Attikí 124 62, Greece
    Recruiting
    • Georgios Tsivgoulis, Site 1203 · Contact+302105832473
  • Eginition Hospital
    Athens, 11528, Greece
    Recruiting
    • NIKOS STEFANIS, Site 1202 · Contact+306936608887
  • Athens Medical Center
    Athens, 15125, Greece
    Recruiting
    • John Papatriantafyllou, Site 1207 · Contact
  • Local Institution - 1201
    Ioannina, 45500, Greece
    Not yet recruiting
    • Site 1201 · Contact

Showing the first 100 of 162 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2028, 40 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 40 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Nov 24, 2028
CompletionEst.
Dec 8, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (3 United States, 1 Croatia, 1 Japan)
  • Hope Research Network - Miami · Virginia Gardens, United States
  • Voltaire Springfield · Springfield, United States
  • Poliklinika Bonifarm-Hondlova 2/11 · Zagreb, Croatia
  • Jichi Medical University Hospital · Shimotsuke-shi, Tochigi, Japan
  • Local Institution - 1656 · New Windsor, United States
Show 5 removed
  • Hope Research Network - Miami · Miami, United States
  • Elixia MA · Springfield, United States
  • Local Institution - 1553 · Zagreb, Croatia
  • Local Institution - 1308 · Shimotsuke-shi, Tochigi, Japan
  • Mid Hudson Medical Research · New Windsor, United States
across 2 updates, Oct 15, 2026 – Nov 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Voltaire Springfield · Springfield, United StatesContact none listed→•••1142
  • Wasatch Clinical Research, LLC · Salt Lake City, United StatesContact •••0607→none listed
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • Local Institution - 1656 · New Windsor, United States
    Show 1 removed
    • Mid Hudson Medical Research · New Windsor, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Voltaire Springfield · Springfield, United StatesContact none listed→•••1142
    • Wasatch Clinical Research, LLC · Salt Lake City, United StatesContact •••0607→none listed
    + 1 other change: verification date
  2. Oct 15, 2026
    4 sites added, 4 sites removed
    Show 4 added (2 United States, 1 Croatia, 1 Japan)
    • Hope Research Network - Miami · Virginia Gardens, United States
    • Voltaire Springfield · Springfield, United States
    • Poliklinika Bonifarm-Hondlova 2/11 · Zagreb, Croatia
    • Jichi Medical University Hospital · Shimotsuke-shi, Tochigi, Japan
    Show 4 removed
    • Hope Research Network - Miami · Miami, United States
    • Elixia MA · Springfield, United States
    • Local Institution - 1553 · Zagreb, Croatia
    • Local Institution - 1308 · Shimotsuke-shi, Tochigi, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07011732
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jul 10, 2025
Primary completion
Nov 24, 2028 (estimated)
Completion
Dec 8, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion